ZyVersa

ZyVersa is a clinical stage company developing first-in-class drugs for inflammatory and renal diseases. Development includes a novel inflammasome inhibitor, IC 100, and a cholesterol efflux mediator for FSGS, an orphan renal disease.

IC 100 is a mAb that uniquely inhibits the ASC component of multiple inflammasomes. As numerous inflammatory diseases are associated with activation of more than one inflammasome, IC 100 is expected to have a therapeutic effect in a broad group of disorders.